Please assess the completion status of the following clinical trial:

Trial Title: Predicting the Response to Montelukast by Genetic Variation in Asthmatics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects, age 18-55~* Clinical history consistent with asthma~* Mild to moderate asthma as determined by pulmonary function tests--60% or higher of predicted FEV1 for age, sex and race.~* Response to hypertonic saline, which will be the main outcome variable measured.~Exclusion Criteria:~* Smokers (total lifetime smoking history\>10 pack-years, any in the past year)~* Pregnant woman-if of childbearing age, not using an acceptable form of birth control.~* Use of a leukotriene modifier within the past month~* Use of inhaled or oral steroids within the past month.~* Emergency room visit for asthma exacerbation within the past 6 weeks.~* Intubation for asthma exacerbation in the past 10 years.~* Adverse reaction to inhaled beta-agonists in the past.~* No recent (past 48 hours) use of anticholinergics, theophylline, antihistamines, pseudoephedrine.~* Patients will also be asked not to use any short acting beta-agonists for 6 hours and long-acting beta-agonists for 48 hours before their initial visit (when pulmonary function evaluation will be performed).~* Lung disease other than asthma~* Significant medical illness other than asthma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).